NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $6.19 +0.14 (+2.31%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$6.19 0.00 (0.00%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About bioAffinity Technologies Stock (NASDAQ:BIAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIAF alerts:Sign Up Key Stats Today's Range$5.85▼$6.2050-Day Range$4.56▼$15.2752-Week Range$4.56▼$80.70Volume105,375 shsAverage Volume2.73 million shsMarket Capitalization$3.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostics and therapeutics for cancer and other serious diseases. The company’s technology uses porphyrin compounds that can selectively interact with cancer cells, supporting applications in both disease detection and treatment. Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test designed to aid in the early detection of lung cancer. The test is intended to identify cancer-related signals in urine and is being developed as an alternative or complement to existing screening and diagnostic methods. bioAffinity is also developing porphyrin-based therapeutic programs, including inhaled treatments intended to target cancer cells in the lungs. Founded in 2007 and headquartered in Albuquerque, New Mexico, the company is led by Maria Zannes, who serves as president and chief executive officer. Its products and programs remain subject to applicable clinical, regulatory, and commercialization requirements.AI Generated. May Contain Errors. Read More bioAffinity Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreBIAF MarketRank™: bioAffinity Technologies scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingbioAffinity Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragebioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.Read more about bioAffinity Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about bioAffinity Technologies' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.17% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently increased by 61.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.01 News SentimentbioAffinity Technologies has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for bioAffinity Technologies this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for BIAF on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders2.68% of the stock of bioAffinity Technologies is held by insiders.Percentage Held by Institutions1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIAF Stock News HeadlinesbioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest UpdateOctober 1, 2026 | americanbankingnews.combioAffinity expands CyPath Lung access for U.S. veteransSeptember 30, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICALSeptember 30, 2026 | businesswire.combioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer DetectionSeptember 28, 2026 | finance.yahoo.combioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual ConferenceSeptember 22, 2026 | finance.yahoo.comBioAffinity Technologies Stock Surges Following Hong Kong Patent GrantSeptember 17, 2026 | benzinga.comFour High-Impact Small Caps Enter the SpotlightSeptember 17, 2026 | markets.businessinsider.comSee More Headlines BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $17.70 at the beginning of the year. Since then, BIAF stock has decreased by 65.0% and is now trading at $6.19. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($31.50) by $30.86. The company had revenue of $1.51 million for the quarter, compared to analysts' expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative trailing twelve-month return on equity of 220.52%. When did bioAffinity Technologies' stock split? bioAffinity Technologies shares reverse split on Friday, September 19th 2025.The 1-30 reverse split was announced on Wednesday, September 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital served as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of bioAffinity Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), Alnylam Pharmaceuticals (ALNY) and Company Calendar Last Earnings8/07/2026Today10/05/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIAF's financial health is in the Yellow zone, according to TradeSmith. BIAF has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:BIAF CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees57Year Founded2014Profitability EPS (Trailing Twelve Months)($109.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.91 million Net Margins-257.30% Pretax Margin-257.18% Return on Equity-220.52% Return on Assets-136.76% Debt Debt-to-Equity Ratio0.14 Current Ratio1.44 Quick Ratio1.41 Sales & Book Value Annual Sales$5.85 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value$24.25 per share Price / Book0.26Miscellaneous Outstanding Shares601,000Free Float585,000Market Cap$3.72 million OptionableNot Optionable Beta-1.25 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BIAF) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMAJOR BUY ALERT: Elon, Data Centers, SpaceStock picker Luke Lango recently toured Vegas and counted more than 60 new data centers under construction, ev...InvestorPlace | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIAF Stock Alerts